Andrew Nguyen

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Collaborators (3)

Andrew Redfern

University of Western Australia

Andrew Martin

Professor of Biostatistics

University of Sydney

JEREMIE CALAIS

David Geffen School of Medicine at UCLA

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrew Nguyen

Research Interests

Explore related searches

Contact this professor

Articles (10)

Collaborators (3)

Andrew Redfern

Andrew Martin

JEREMIE CALAIS

Make your next move.

Andrew Nguyen

Research Interests

Explore related searches

Contact this professor

Articles (10)

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP)

Utility of<sup>64</sup>Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on<sup>68</sup>Ga-PSMA-11 PET/CT

Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer

Development of a Visually Calculated SUV<sub>mean</sub>(HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to<sup>177</sup>Lu-PSMA Therapy: Comparison with Quantitative SUV<sub>mean</sub>and Patient Outcomes

Treatment Response Imaging in Prostate Cancer

Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database

Evaluation of <sup>177</sup>Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&amp;T Therapy

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&amp;T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)

Collaborators (3)

Andrew Redfern

Andrew Martin

JEREMIE CALAIS

Make your next move.

<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&T Therapy

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)